S. Kulp

发表

3-Phosphoinositide-Dependent Protein Kinase-1/Akt Signaling Represents a Major Cyclooxygenase-2-Independent Target for Celecoxib in Prostate Cancer Cells

S. Kulp, Y. Yang, Chin-Chun Hung, 2004, Cancer Research.

Soy-tomato enriched diet reduces inflammation and disease severity in a pre-clinical model of chronic pancreatitis

S. Kulp, P. Hart, D. Conwell, 2020, Scientific Reports.

Pharmacokinetics and Tolerability of the Novel Non-immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and Rats

J. Byrd, S. Kulp, Dasheng Wang, 2020, The AAPS Journal.

FTY 720 Induces Apoptosis in Hepatocellular Carcinoma Cells through Activation of Protein Kinase C D Signaling

J. Byrd, S. Kulp, C. Chen, 2008 .

FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling.

J. Byrd, S. Kulp, C. Chen, 2008, Cancer research.

A Novel Mechanism by Which Thiazolidinediones Facilitate the Proteasomal Degradation of Cyclin D1 in Cancer Cells*

Pei-Jung Lu, S. Kulp, C. Chen, 2008, Journal of Biological Chemistry.

The mRNA-stabilizing Factor HuR Protein Is Targeted by β-TrCP Protein for Degradation in Response to Glycolysis Inhibition*

S. Kulp, C. Chen, Po-Chen Chu, 2012, The Journal of Biological Chemistry.

Peroxisome Proliferator-Activated Receptor γ-Independent Ablation of Cyclin D1 by Thiazolidinediones and Their Derivatives in Breast Cancer Cells

C. Shapiro, S. Kulp, Y. Yang, 2005, Molecular Pharmacology.

OSU‐DY7, a novel D‐tyrosinol derivative, mediates cytotoxicity in chronic lymphocytic leukaemia and Burkitt lymphoma through p38 mitogen‐activated protein kinase pathway

J. Byrd, S. Kulp, C. Chen, 2011, British journal of haematology.

Inhibition of human prostate cancer cells growth by gossypol is associated with stimulation of transforming growth factor-β

Yuan Zhang, S. Kulp, H. Canatan, 1996 .

Gossypol arrests human benign prostatic hyperplastic cell growth at G0/G1 phase of the cell cycle.

S. Kulp, H. Canatan, Y. Sugimoto, 1997, Anticancer research.

SUV39H1 Represses the Expression of Cytotoxic T-Lymphocyte Effector Genes to Promote Colon Tumor Immune Evasion

S. Kulp, M. Grinstaff, M. Phelps, 2019, Cancer Immunology Research.

Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer

S. Kulp, C. Chen, T. Bekaii-Saab, 2018, Small GTPases.

A novel HIF-1α-integrin-linked kinase regulatory loop that facilitates hypoxia-induced HIF-1α expression and epithelial-mesenchymal transition in cancer cells

S. Kulp, C. Chen, S. Salunke, 2015, Oncotarget.

Met interacts with EGFR and Ron in canine osteosarcoma.

S. Kulp, C. Khanna, J. McCleese, 2013, Veterinary and comparative oncology.

Antitumor effects of OSU‐2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma

J. Byrd, S. Kulp, C. Chen, 2011, Hepatology.

AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit.

S. Kulp, C. Chen, Dasheng Wang, 2010, Blood.

Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer.

S. Kulp, C. Chen, M. Poi, 2016, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

AMPK as a potential anticancer target - friend or foe?

S. Kulp, C. Chen, H. Chuang, 2014, Current pharmaceutical design.

Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans

S. Kulp, M. Phelps, C. Coss, 2021, JCSM rapid communications.

Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines.

S. Kulp, C. Chen, W. Kisseberth, 2008, American journal of veterinary research.

Functional Role of mTORC2 versus Integrin-Linked Kinase in Mediating Ser473-Akt Phosphorylation in PTEN-Negative Prostate and Breast Cancer Cell Lines

J. Byrd, Su-Lin Lee, S. Kulp, 2013, PloS one.

A Review of the Existing Grading Schemes and a Proposal for a Modified Grading Scheme for Prostatic Lesions in TRAMP Mice

S. Kulp, C. Chen, T. Rosol, 2012, Toxicologic pathology.

Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells.

D. Welling, S. Kulp, C. Chen, 2009, European journal of cancer.

Keratinocyte growth factor (KGF/FGF-7) has a paracrine role in canine prostate: molecular cloning of mRNA encoding canine KGF.

S. Kulp, H. Canatan, Y. Sugimoto, 1996, DNA and cell biology.

The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer

M. Dillhoff, S. Kulp, G. Behbehani, 2021, International journal of molecular sciences.

2-Amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} Acetamide (OSU-03012), a Celecoxib Derivative, Directly Targets p21-Activated Kinase

S. Kulp, C. Chen, M. Saji, 2007, Molecular Pharmacology.

Development of novel adenosine monophosphate-activated protein kinase activators.

Su-Lin Lee, S. Kulp, C. Chen, 2010, Journal of medicinal chemistry.

The inhibitory effects of gossypol on human prostate cancer cells-PC3 are associated with transforming growth factor beta1 (TGFbeta1) signal transduction pathway.

S. Kulp, Y. Sugimoto, Jiahua Jiang, 2004, Anticancer research.

Keratinocyte growth factor (KGF) induces aromatase activity in cultured MCF-7 human breast cancer cells.

S. Kulp, Y. Sugimoto, R. Brueggemeier, 1998, Anticancer research.

Estrogen-induced keratinocyte growth factor mRNA expression in normal and cancerous human breast cells.

S. Kulp, Y. Sugimoto, R. Brueggemeier, 1998, Oncology reports.

OSU03012, a novel PDK1 inhibitor, decreases thyroid cancer proliferation and migration via multiple downstream pathways.

S. Kulp, C. Chen, M. Saji, 2006 .

Peroxisome Proliferator-Activated Receptor-Independent Ablation of Cyclin D 1 by Thiazolidinediones and Their Derivatives in Breast Cancer Cells

C. Shapiro, S. Kulp, Kuen-Feng Chen, 2005 .

Peroxisome Proliferator-Activated Receptor γ -Independent Ablation of Cyclin D1 by Thiazolidenediones and Their Derivatives in Breast Cancer Cells

C. Shapiro, S. Kulp, Kuen-Feng Chen, 2004 .

Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro.

S. Kulp, M. Pennell, M. Bear, 2010, American journal of veterinary research.

Identification and characterization of a novel integrin-linked kinase inhibitor.

Su-Lin Lee, S. Kulp, C. Chen, 2011, Journal of medicinal chemistry.

Overcoming Resistance to Anabolic Selective Androgen Receptor Modulator (SARM) Therapy in Experimental Cancer Cachexia with Histone Deacetylase Inhibitor AR-42

Michael G. Sovic, S. Kulp, C. Chen, 2018, bioRxiv.

Eradication of Intracellular Salmonellaenterica Serovar Typhimurium with a Small-Molecule, Host Cell-Directed Agent

S. Kulp, C. Chen, Dasheng Wang, 2009, Antimicrobial Agents and Chemotherapy.

Extra-prostatic Transgene-associated Neoplastic Lesions in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) Mice

S. Kulp, C. Chen, K. L. La Perle, 2015, Toxicologic pathology.

Retraction: Sensitizing Estrogen Receptor–negative Breast Cancer Cells to Tamoxifen with OSU-03012, a Novel Celecoxib-derived Phosphoinositide-dependent Protein Kinase-1/Akt Signaling Inhibitor

C. Shapiro, S. Kulp, C. Chen, 2008, Molecular Cancer Therapeutics.

Sensitizing estrogen receptor–negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor

C. Shapiro, S. Kulp, C. Chen, 2008, Molecular Cancer Therapeutics.

Inhibition of androgen/AR signaling inhibits diethylnitrosamine (DEN) induced tumour initiation and remodels liver immune cell networks

S. Kulp, M. Campbell, M. Phelps, 2021, Scientific Reports.

Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability

S. Kulp, C. Chen, C. Teng, 2015, Oncotarget.

Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy.

D. Carbone, S. Kulp, P. Shields, 2022, Clinical lung cancer.

Transforming Growth Factor ß1 Facilitates Cell Proliferation and Invasion in MAT-LyLu Prostatic Cancer Cells

S. Kulp, Y. Sugimoto, R. Brueggemeier, 1996 .

Differential effect of keratinocyte growth factor (KGF) on aromatase activity in cultured canine prostatic epithelial cells.

S. Kulp, H. Canatan, Y. C. Lin, 1997, Endocrine research.

Sensitization of Intracellular Salmonella enterica Serovar Typhimurium to Aminoglycosides In Vitro and In Vivo by a Host-Targeted Antimicrobial Agent

S. Kulp, Hao-Chieh Chiu, Ching S. Chen, 2014, Antimicrobial Agents and Chemotherapy.

Involvement of breast epithelial-stromal interactions in the regulation of protein tyrosine phosphatase-γ (PTPγ) mRNA expression by estrogenically active agents

S. Kulp, Y. Sugimoto, Jiahua Jiang, 2004, Breast Cancer Research and Treatment.

Transfer of 3H-gossypol to neonatal rats via milk of nursing dams.

S. Kulp, Y. Hu, Y. C. Lin, 1992, Life sciences.

Targeting of the Akt-Nuclear Factor-κB Signaling Network by [1-(4-Chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol (OSU-A9), a Novel Indole-3-Carbinol Derivative, in a Mouse Model of Hepatocellular Carcinoma

S. Kulp, Dasheng Wang, T. Patel, 2009, Molecular Pharmacology.

Indole-3-carbinol as a chemopreventive and anti-cancer agent.

S. Kulp, Ching-Shih Chen, J. Weng, 2008, Cancer letters.

Effects of Thiazolidinediones on Differentiation, Proliferation, and Apoptosis

S. Kulp, Pei-Shan Wang, F. Chou, 2007, Molecular Cancer Research.

Detection of keratinocyte growth factor (KGF) messenger ribonucleic acid and immunolocalization of KGF in the canine testis

S. Kulp, H. Canatan, Y. Sugimoto, 1996, Endocrine.

The (-)-enantiomer of gossypol possesses higher anticancer potency than racemic gossypol in human breast cancer.

S. Kulp, Y. Sugimoto, M. Dowd, 2002, Anticancer research.

Gossypol induces spermidine/spermine N1-acetyltransferase in canine prostate epithelial cells.

S. Kulp, H. Canatan, Y. Sugimoto, 1997, Biochemical and biophysical research communications.

Histone Deacetylase Inhibitors Stimulate Histone H3 Lysine 4 Methylation in Part Via Transcriptional Repression of Histone H3 Lysine 4 Demethylases

J. Byrd, S. Kulp, C. Teng, 2011, Molecular Pharmacology.

Energy Restriction-mimetic Agents Induce Apoptosis in Prostate Cancer Cells in Part through Epigenetic Activation of KLF6 Tumor Suppressor Gene Expression*

S. Kulp, Dasheng Wang, Qianben Wang, 2011, The Journal of Biological Chemistry.

From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of 3-Phosphoinositide-Dependent Protein Kinase-1 Inhibitors

S. Kulp, Ping-Hui Tseng, Joseph W. Fowble, 2004, Cancer Research.

Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells

C. Shapiro, S. Kulp, N. Kapuriya, 2012, Breast Cancer Research and Treatment.

Zeranol Induces Deleterious Effects on the Testes and the Prostate Gland of Mature Rats

S. Kulp, Young C. Lin, F. Shidaifat, 2013, Endocrine research.

Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells.

Pui-Kai Li, Li Lin, S. Kulp, 2010, Cancer research.

Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors.

S. Kulp, Dasheng Wang, M. Yamaguchi, 2008, Cancer research.

Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma.

S. Kulp, Kuen-Feng Chen, C. Shiau, 2005, Cancer research.

A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.

K. Nephew, S. Kulp, C. Balch, 2009, Neoplasia.

Targeting Energy Metabolic and Oncogenic Signaling Pathways in Triple-negative Breast Cancer by a Novel Adenosine Monophosphate-activated Protein Kinase (AMPK) Activator*

C. Shapiro, S. Kulp, Dasheng Wang, 2011, The Journal of Biological Chemistry.

Suppression of Prostate Epithelial Proliferation and Intraprostatic Progrowth Signaling in Transgenic Mice by a New Energy Restriction-Mimetic Agent

S. Kulp, Dasheng Wang, J. Thomas-Ahner, 2012, Cancer Prevention Research.

Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells.

Xueqin Song, S. Kulp, Ping-Hui Tseng, 2002, Journal of the National Cancer Institute.

Prospects on Strategies for Therapeutically Targeting Oncogenic Regulatory Factors by Small‐Molecule Agents

S. Kulp, S. Salunke, Chih‐Chien Chou, 2014, Journal of cellular biochemistry.

Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.

S. Kulp, T. Bekaii-Saab, X. Mo, 2014, Carcinogenesis.

Antitumor Effects of a Novel Phenylbutyrate-Based Histone Deacetylase Inhibitor, (S)-HDAC-42, in Prostate Cancer

S. Kulp, Dasheng Wang, Chang‐Shi Chen, 2006, Clinical Cancer Research.

The effect of phosphorylated Akt inhibition on posterior capsule opacification in an ex vivo canine model

S. Kulp, C. Colitz, H. Chandler, 2010, Molecular vision.

Vitamin E Facilitates the Inactivation of the Kinase Akt by the Phosphatase PHLPP1

Su-Lin Lee, S. Kulp, Dasheng Wang, 2013, Science Signaling.

PPARgamma-independent antitumor effects of thiazolidinediones.

Su-Lin Lee, S. Kulp, Shuo Wei, 2009, Cancer letters.

Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer.

S. Kulp, Po-Hsien Huang, H. Chuang, 2017, Pharmacological research.

Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation.

Ching-Yu Chen, S. Kulp, S. Matsuyama, 2007, Cancer research.

OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model.

S. Kulp, Yu-Chieh Wang, S. Clinton, 2008, Cancer research.

Abstract 1360: Novel function of p21-activated kinase 3 (PAK3) in regulating Akt phosphorylation and pancreatic cancer stem cell phenotypes

S. Kulp, Po-Chen Chu, Hsing-Yu Wu, 2017 .

Integrin-linked kinase as a novel molecular switch of the IL-6-NF-κB signaling loop in breast cancer.

C. Shapiro, M. Wicha, S. Kulp, 2016, Carcinogenesis.

AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis.

C. Shapiro, S. Kulp, Dasheng Wang, 2014, Cancer research.

Reverses the Mesenchymal Phenotype of Cancer Cells by Targeting the Akt – MDM 2 – Foxo 3 a Signaling Axis

C. Shapiro, S. Kulp, Dasheng Wang, 2014 .

Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells

S. Kulp, M. Lai, T. Bekaii-Saab, 2016, Oncogene.

A potent indole-3-carbinol derived antitumor agent with pleiotropic effects on multiple signaling pathways in prostate cancer cells.

S. Kulp, Dasheng Wang, M. Tsai, 2007, Cancer research.

Histone deacetylase inhibitor AR42 regulates telomerase activity in human glioma cells via an Akt-dependent mechanism.

S. Kulp, Po-Hsien Huang, Ya-Luen Yang, 2013, Biochemical and biophysical research communications.

alpha-Tocopheryl succinate as a scaffold to develop potent inhibitors of breast cancer cell adhesion.

S. Kulp, Dasheng Wang, Po-Hsien Huang, 2009, Journal of medicinal chemistry.

Thiazolidinediones Mimic Glucose Starvation in Facilitating Sp1 Degradation through the Up-Regulation of β-Transducin Repeat-Containing Protein

S. Kulp, A. Paterson, W. Tsai, 2009, Molecular Pharmacology.

alpha-Tocopheryl succinate and derivatives mediate the transcriptional repression of androgen receptor in prostate cancer cells by targeting the PP2A-JNK-Sp1-signaling axis.

S. Kulp, Dasheng Wang, Po-Hsien Huang, 2009, Carcinogenesis.

Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas

D. Welling, S. Kulp, K. L. La Perle, 2012, The Laryngoscope.

Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus.

Su-Lin Lee, S. Kulp, Dasheng Wang, 2012, Bioorganic & medicinal chemistry.

The effects of gossypol on the invasiveness of MAT-LyLu cells and MAT-LyLu cells from the metastasized lungs of MAT-LyLu-bearing Copenhagen rats.

S. Kulp, Y. Sugimoto, Y. C. Lin, 2000, Anticancer research.

3-Phosphoinositide-dependent protein kinase-1/Akt signalling and inhibition in a canine prostate carcinoma cell line.

S. Kulp, T. Rosol, C. Couto, 2007, Veterinary and comparative oncology.

Transforming growth factor-β1 regulates differentiation of porcine granulosa cells in vitro

S. Kulp, William Y. Chang, Young C. Lin, 1993 .

Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis

S. Kulp, J. Modiano, W. Kisseberth, 2017, BMC Cancer.

Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia.

S. Kulp, G. Lesinski, T. Bekaii-Saab, 2015, Journal of the National Cancer Institute.

Chemopreventive and Bioenergetic Signaling Effects of PDK1/Akt Pathway Inhibition in a Transgenic Mouse Model of Prostate Cancer

S. Kulp, M. Yamaguchi, S. Clinton, 2007, Toxicologic pathology.

AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.

D. Welling, S. Kulp, Sarah S. Burns, 2011, Neuro-oncology.

Liposomes Containing (-)-Gossypol-Enriched Cottonseed Oil Suppress Bcl-2 and Bcl-xL Expression in Breast Cancer Cells

L. J. Lee, S. Kulp, Robert J. Lee, 2011, Pharmaceutical Research.

Pharmacological exploitation of the peroxisome proliferator-activated receptor gamma agonist ciglitazone to develop a novel class of androgen receptor-ablative agents.

S. Kulp, Dasheng Wang, Yu-Chieh Wang, 2008, Journal of medicinal chemistry.

OSU-A9, a potent indole-3-carbinol derivative, suppresses breast tumor growth by targeting the Akt-NF-kappaB pathway and stress response signaling.

C. Shapiro, S. Kulp, Dasheng Wang, 2009, Carcinogenesis.

Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor

Michael G. Sovic, S. Kulp, T. Bekaii-Saab, 2020, EMBO molecular medicine.

The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo

Derek A. West, Michael A. Freitas, M. Grever, 2010, PloS one.

Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition

J. Byrd, S. Kulp, J. Blachly, 2021, Clinical Cancer Research.

Pharmacological Exploitation of an Off-Target Antibacterial Effect of the Cyclooxygenase-2 Inhibitor Celecoxib against Francisella tularensis

S. Kulp, J. Gunn, L. Schlesinger, 2009, Antimicrobial Agents and Chemotherapy.

Eradication of intracellular Francisella tularensis in THP-1 human macrophages with a novel autophagy inducing agent

S. Kulp, Dasheng Wang, J. Gunn, 2009, Journal of Biomedical Science.

Role of integrin-linked kinase in regulating the protein stability of the MUC1-C oncoprotein in pancreatic cancer cells

S. Kulp, C. Teng, C.-S. Chen, 2017, Oncogenesis.

Sensitization of Intracellular Salmonella to Aminoglycosides in vitro and in vivo by a 1

S. Kulp, Hao-Chieh Chiu, Ching S. Chen, 2014 .

Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines

S. Kulp, Jiayuh Lin, M. Bear, 2012, BMC Veterinary Research.

Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-4212

S. Kulp, T. Bekaii-Saab, X. Mo, 2016, Neoplasia.

Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma

S. Kulp, Dasheng Wang, A. Cheng, 2007, Hepatology.

Histone Deacetylase Inhibitors Sensitize Prostate Cancer Cells to Agents that Produce DNA Double-Strand Breaks by Targeting Ku 70 Acetylation

S. Kulp, S. Matsuyama, Yu-Chieh Wang, 2007 .

Exploitation of the ability of γ-tocopherol to facilitate membrane co-localization of Akt and PHLPP1 to develop PHLPP1-targeted Akt inhibitors.

S. Kulp, Chia-Ning Yang, H. Chang, 2015, Journal of medicinal chemistry.

Novel STAT 3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells

Li Lin, S. Kulp, Bulbul Pandit, 2010 .

Combined Androgen Administration and HDAC Inhibition in Experimental Cancer Cachexia

S. Kulp, C. Coss, J. Benedict, 2017 .

In vitro uptake and autoradiographic localization of tritiated gossypol inTaenia taeniaeformis metacestodes

S. Kulp, Y. Rikihisa, Y. C. Lin, 2004, Parasitology Research.

Pharmacological exploitation of indole-3-carbinol to develop potent antitumor agents.

S. Kulp, J. Weng, H. Omar, 2010, Mini reviews in medicinal chemistry.

The (-)-enantiomer of gossypol inhibits proliferation of stromal cells derived from human breast adipose tissues by enhancing transforming growth factor beta1 production.

S. Kulp, Y. Sugimoto, R. Brueggemeier, 1998, International journal of oncology.

17 beta-estradiol-regulated expression of protein tyrosine phosphatase gamma gene in cultured human normal breast and breast cancer cells.

S. Kulp, J. Zheng, Y. Sugimoto, 2000, Anticancer research.

Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms.

S. Kulp, Ping-Hui Tseng, Ho-pi Lin, 2004, Molecular cancer therapeutics.

Function of Integrin-Linked Kinase in Modulating the Stemness of IL-6–Abundant Breast Cancer Cells by Regulating γ-Secretase–Mediated Notch1 Activation in Caveolae12

C. Shapiro, M. Wicha, S. Kulp, 2015, Neoplasia.

Radiosensitizing effect of a phenylbutyrate-derived histone deacetylase inhibitor in hepatocellular carcinoma.

S. Kulp, J. Cheng, A. Cheng, 2012, International journal of radiation oncology, biology, physics.

Energy restriction as an antitumor target.

S. Kulp, H. Omar, L. Berman-Booty, 2010, Future oncology.

Energy Restriction as an Antitumor Target of Thiazolidinediones*

S. Kulp, Shuo Wei, Ching S. Chen, 2010, The Journal of Biological Chemistry.

Development of a novel class of glucose transporter inhibitors.

S. Kulp, Dasheng Wang, Chia-Ning Yang, 2012, Journal of medicinal chemistry.

Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells.

C. Shapiro, S. Kulp, Kuen-Feng Chen, 2005, Molecular Pharmacology.

PPAR γ-Independent Antitumor Effects of Thiazolidinediones

Su-Lin Lee, S. Kulp, Shuo Wei, 2009 .

Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents

R. Garzon, S. Kulp, Dasheng Wang, 2016, The AAPS Journal.

Exploration of Verticillins in High-Grade Serous Ovarian Cancer and Evaluation of Multiple Formulations in Preclinical In Vitro and In Vivo Models.

S. Kulp, M. Phelps, D. Lantvit, 2023, Molecular pharmaceutics.

Targeting the Oncogenic E3 Ligase Skp2 in Prostate and Breast Cancer Cells with a Novel Energy Restriction-Mimetic Agent

S. Kulp, W. Hung, Po-Chen Chu, 2012, PloS one.

Insulin-like growth factor-I receptor is suppressed through transcriptional repression and mRNA destabilization by a novel energy restriction-mimetic agent.

S. Kulp, Po-Chen Chu, Ching S. Chen, 2019, Carcinogenesis.

Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIα degradation in hepatocellular carcinoma cells

S. Kulp, C. Teng, H. Chuang, 2011, Hepatology.

Cyclooxygenase-2 in Cancer: A Role Yet to Be Defined

S. Kulp, Ho-pi Lin, Ching S. Chen, 2003 .

Development of Potent Adenosine Monophosphate Activated Protein Kinase (AMPK) Activators

S. Kulp, K. Abouzid, N. S. Ismail, 2015, ChemMedChem.

Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML

M. Caligiuri, R. Bundschuh, S. Kulp, 2013, Leukemia.

2-Amino-N- Acetamide (OSU-03012), a Celecoxib Derivative, Directly Targets p21-Activated Kinase

S. Kulp, M. Saji, M. Ringel, 2007 .

Effects of gossypol on O2 consumption and CO2 production in human prostate cancer cells.

S. Kulp, Y. Sugimoto, Jiahua Jiang, 2002, Anticancer research.

Involvement of breast epithelial-stromal interactions in the regulation of protein tyrosine phosphatase-gamma (PTPgamma) mRNA expression by estrogenically active agents.

S. Kulp, Y. Sugimoto, Jiahua Jiang, 2002, Breast Cancer Research and Treatment.